ZD 1611

an endothelin ET(A) receptor antagonist; structure in first source

Also Known As:

3-(4-(3-(3-methoxy-5-methylpyrazin-2-ylsulfamoyl)-2-pyridyl)phenyl)-2,2-dimethylpropanoic acid; ZD-1611; ZD1611

Networked: 4 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrazines: 150
    - ZD 1611: 4
Organic Chemicals: 133
- Amides: 2428
  - Sulfonamides: 2809
    - ZD 1611: 4
- Sulfur Compounds: 278
  - Sulfones: 534
    - Sulfonamides: 2809
      - ZD 1611: 4

Experts

1.	Edvinsson, Lars: 1 article (09/2007)
2.	Henriksson, Marie: 1 article (09/2007)
3.	Jamali, Roya: 1 article (09/2007)
4.	Maddahi, Aida: 1 article (09/2007)
5.	Stenman, Emelie: 1 article (09/2007)
6.	Betton, Graham R: 1 article (05/2003)
7.	Davis, A Stewart: 1 article (05/2003)
8.	Greaves, Peter: 1 article (05/2003)
9.	Jones, Huw B: 1 article (05/2003)
10.	Macpherson, Allen: 1 article (05/2003)

Related Diseases

1.	Hypoxia (Hypoxemia) 01/01/1999 - "In conclusion, the ET(A)receptor-selective antagonist, ZD1611, attenuates hypoxia-induced PH in the rat." 01/01/1999 - "We evaluated the effects of an ET(A)receptor-selective antagonist, ZD1611, on hypoxia-induced PH in rats. " 01/01/1999 - "In mechanistic studies, ZD1611 decreased (P<0.01) smooth muscle hypertrophy of small pulmonary arteries and abolished hypoxia-induced decreases in sensitivity and maximum contraction to ET-1 in isolated extralobar branch pulmonary artery. " 01/01/1999 - "ZD1611, an orally active endothelin-A receptor antagonist, prevents chronic hypoxia-induced pulmonary hypertension in the rat." 07/01/1998 - "A novel orally active endothelin-A receptor antagonist, ZD1611, prevents chronic hypoxia-induced pulmonary hypertension in the rat."
2.	Hypertrophy 01/01/1999 - "In mechanistic studies, ZD1611 decreased (P<0.01) smooth muscle hypertrophy of small pulmonary arteries and abolished hypoxia-induced decreases in sensitivity and maximum contraction to ET-1 in isolated extralobar branch pulmonary artery. "
3.	Pulmonary Hypertension 01/01/1999 - "ZD1611, an orally active endothelin-A receptor antagonist, prevents chronic hypoxia-induced pulmonary hypertension in the rat." 07/01/1998 - "A novel orally active endothelin-A receptor antagonist, ZD1611, prevents chronic hypoxia-induced pulmonary hypertension in the rat." 05/01/2003 - "Two endothelin antagonists, ZD1611 (3-[4-[3-(3-methoxy-5-methylpyrazin-2-ylsulfamoyl)-2-pyridyl]phenyl]-2,2-dimethylpropanoic acid) and ZD2574 (2-(4-isobutylphenyl)-N-(3-methoxy-5-methylpyrazin-2-yl)pyridine-3-sulfonamide), selective for the ET(A) receptor and intended for use in pulmonary hypertension, were tested in Beagle dogs at various doses for periods of up to 4 weeks. "
4.	Infarction (Infarctions) 09/10/2007 - "We hypothesise that this phenomenon may be detrimental and that acute treatment with a combined non-hypotensive dose of the angiotensin AT(1) receptor inhibitor candesartan and the endothelin ET(A) receptor antagonist ZD1611 reduces the infarct in experimental ischemic stroke. "
5.	Ischemic Stroke 09/10/2007 - "We hypothesise that this phenomenon may be detrimental and that acute treatment with a combined non-hypotensive dose of the angiotensin AT(1) receptor inhibitor candesartan and the endothelin ET(A) receptor antagonist ZD1611 reduces the infarct in experimental ischemic stroke. "

Related Drugs and Biologics

1.	Endothelin A Receptor
2.	Endothelin Receptor Antagonists
3.	Endothelins (Endothelin)
4.	Angiotensins
5.	Acids
6.	candesartan